SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The objective of this trial was to determine the effectiveness of 1.0% C31G (SAVVY) in preventing male-to-female vaginal transmission of HIV infection among women at high risk. METHODOLOGY/PRINCIPAL FINDINGS: This was a Phase 3, double-blind, randomized, placebo-controlled trial. Participants made up to 12 monthly follow-up visits for HIV testing, adverse event reporting, and study product supply. The study was conducted between September 2004 and December 2006 in Lagos and Ibadan, Nigeria, where we enrolled 2153 HIV-negative women at high risk of HIV infection. Participants were randomized 1 ratio 1 to SAVVY or placebo. The effectiveness endpoint was incidence of HIV infection as indicated by detection of HIV antibodies in oral mucosal transudate (rapid test) or blood (ELISA), and confirmed by Western blot or PCR testing. We observed 33 seroconversions (21 in the SAVVY group, 12 in the placebo group). The Kaplan-Meier estimates of the cumulative probability of HIV infection at 12 months were 0.028 in the SAVVY group and 0.015 in the placebo group (2-sided p-value for the log-rank test of treatment effect 0.121). The point estimate of the hazard ratio was 1.7 for SAVVY versus placebo (95% confidence interval 0.9, 3.5). Because of lower-than-expected HIV incidence, we did not observe the required number of HIV infections (66) for adequate power to detect an effect of SAVVY. Follow-up frequencies of adverse events, reproductive tract adverse events, abnormal pelvic examination findings, chlamydial infections and vaginal infections were similar in the study arms. No serious adverse event was attributable to SAVVY use. CONCLUSIONS/SIGNIFICANCE: SAVVY did not reduce the incidence of HIV infection. Although the hazard ratio was higher in the SAVVY than the placebo group, we cannot conclude that there was a harmful treatment effect of SAVVY.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonspecific topical microbicides are ineffective for preventing HIV infection (40–45).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“We calculated Kaplan-Meier estimates [17] of HIV infection probabilities by treatment group, pooled across sites.”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755 · cited 1×
“[1] We conducted this study under an IND to the U.”
MethodDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 1×
“[14–15] The analysis plan included a blinded assessment of whether additional participants would be needed to observe the required 66 events.”
MethodVan Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Tshibaka, L. M., Ettiègne-Traoré, V., Uaheowitchai, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11079-8 · Cited by 797 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
Kreiss, J. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490040053025 · Cited by 402 · cited 1×
“[6,7] C31G (SAVVYH) has a potent effect on enveloped HIV in vitro through a mechanism by which it disrupts the outer membrane.”
BackgroundRoddy, R. E., Zekeng, L., Ryan, K. A., Tamoufé, U., Weir, S. S., & Wong, E. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808203390803 · Cited by 366
Peterson, L., Taylor, D., Roddy, R., Belai, G., Phillips, P., Nanda, K., Grant, R., Clarke, E. E. K., Doh, A. S., Ridzon, R., et al. (2007) · PLoS Clinical Trials · doi:10.1371/journal.pctr.0020027 · Cited by 277 · cited 1×
“[20] Diminished HIV incidence within a clinical trial may follow from vigorous responses to trial risk-reduction measures, as well as the phenomenon that participants who join clinical trials differ from others in the wider community, [21] in this case a possible inclination to safer behavior.”
BackgroundSelf-citationPinsky, P., Miller, A., Kramer, B., Church, T., Reding, D., Prorok, P., Gelmann, E., Schoen, R., Buys, S., Hayes, R., et al. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk075 · Cited by 228 · cited 1×
“[20] Diminished HIV incidence within a clinical trial may follow from vigorous responses to trial risk-reduction measures, as well as the phenomenon that participants who join clinical trials differ from others in the wider community, [21] in this case a possible inclination to safer behavior.”
BackgroundPeterson, L., Nanda, K., Opoku, B. K., Ampofo, W. K., Owusu-Amoako, M., Boakye, A. Y., Rountree, W., Troxler, A., Dominik, R., Roddy, R., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001312 · Cited by 187
Self-citationMicrobicide drug candidates to prevent HIV infection
Balzarini, J., & Van Damme, L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60202-5 · Cited by 184 · cited 1×
“[4] Microbicides could potentially be applied vaginally to prevent both male-to-female and female-to-male transmission; by offering a female-controlled prophylactic option, a microbicide would be an important addition to the prevention toolkit.”
BackgroundWilkinson, D., Tholandi, M., Ramjee, G., & Rutherford, G. W. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00396-1 · Cited by 107 · cited 1×
“Unfortunately, no clinical studies to date have demonstrated that these products can prevent HIV infection, [5] and spermicides with the surfactant nonoxynol-9 (N-9) have caused mucosal erosion and ulceration, which may increase the risk of HIV acquisition.”
BackgroundKrebs, F. C., Miller, S. R., Catalone, B. J., Welsh, P. A., Malamud, D., Howett, M. K., & Wigdahl, B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.7.1954-1960.2000 · Cited by 80 · cited 1×
“[8] Because its mechanism of action is similar to N-9, [8,9] some have raised concerns about the safety of C31G.”
BackgroundHeterosexual HIV transmission.
Kh, M., & Anderson, D. J. (1995) · PubMed · Cited by 74
O'Brien, T. R., Busch, M. P., Donegan, E. A., Ward, J. W., Wong, L.-Y., Samson, S., Perkins, H. A., Altman, R., Stoneburner, R. L., & Holmberg, S. D. (1994) · PubMed · Cited by 66
Fourteen-day safety and acceptability study of the universal placebo gel
Schwartz, J. L., Ballagh, S. A., Kwok, C., Mauck, C. K., Weiner, D. H., Rencher, W. F., & Callahan, M. M. (2006) · Contraception · doi:10.1016/j.contraception.2006.09.003 · Cited by 65
Male homosexual transmission of HIV-1
Cáceres, C. F., & van Griensven, G. J. P. (1994) · AIDS · doi:10.1097/00002030-199408000-00004 · Cited by 58 · cited 1×
“[23–25] Therefore, some of the seroconversions seen in this vaginal microbicide study could be due to HIV exposure through anal intercourse, with an equal probability of infection regardless of treatment group and resulting bias towards no apparent effect on vaginal transmission.”
BackgroundCondoms and sexually-transmitted infections
Steiner, M. J., & Cates, W. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068111 · Cited by 57 · cited 1×
“Correct and consistent male condom use has been shown to prevent HIV-1 transmission, [3] but women are often unable to obligate or negotiate the use of condoms by their male partners.”
BackgroundRoddy, R. E., Zekeng, L. A., Ryan, K. A., Tamoufe, U., Weir, S. S., & Wong, E. L. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(01)61754-3 · Cited by 52 · cited 1×
“One N-9 trial reported no difference in HIV incidence, [26] while the second reported a higher incidence in the treatment group.”
Mauck, C. K., Weiner, D. H., Creinin, M. D., Barnhart, K. T., Callahan, M. M., & Bax, R. P. (2004) · Contraception · doi:10.1016/j.contraception.2004.04.010 · Cited by 48
Microbicides—evaluating multiple formulations of C31G
Bax, R. P., Douville, K. L., McCormick, D., Rosenberg, M., Higgins, J., & Bowden, M. (2002) · Contraception · doi:10.1016/s0010-7824(02)00389-x · Cited by 46 · cited 1×
“[8] Because its mechanism of action is similar to N-9, [8,9] some have raised concerns about the safety of C31G.”
BackgroundSubgroup analysis in obstetrics clinical trials
Klebanoff, M. A. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.02.030 · Cited by 43 · cited 1×
“[18] The small number of events and the absence of supporting evidence in the similar FHI SAVVY trial in Ghana [19] make this a challenging question that we are unlikely to answer conclusively.”
BackgroundSafety of single daily use for one week of C31G HEC gel in women
Ballagh, S. A., Baker, J. M., Henry, D. M., & Archer, D. F. (2002) · Contraception · doi:10.1016/s0010-7824(02)00433-x · Cited by 40 · cited 1×
“[13] The 1.”
Pregnancy in Effectiveness Trials of HIV Prevention Agents
Raymond, E. G., Taylor, D. J., Cates, W., Tolley, E. E., Borasky, D., CANCEL, A., Mâsse, B. R., Bukusi, E. A., & Johnson, B. R. (2007) · Sexually Transmitted Diseases · doi:10.1097/olq.0b013e3180e90586 · Cited by 33 · cited 1×
“[22] We suspect over-reporting of adherence in this trial: despite SAVVY’s purported contraceptive effect, [11] the similar pregnancy rates in the two groups raises doubt that the gels were used as consistently as reported.”
ResultA phase I comparative postcoital testing study of three concentrations of C31G
Mauck, C. K., Creinin, M. D., Barnhart, K. T., Ballagh, S. A., Archer, D. F., Callahan, M. M., Schmitz, S. W., & Bax, R. P. (2004) · Contraception · doi:10.1016/j.contraception.2004.02.001 · Cited by 29 · cited 1×
“We suspect over-reporting of adherence in this trial: despite SAVVY's purported contraceptive effect,”
ResultMale tolerance study of 1% C31G
Mauck, C. K., Frezieres, R. G., Walsh, T. L., Schmitz, S. W., Callahan, M. M., & Bax, R. P. (2004) · Contraception · doi:10.1016/j.contraception.2003.12.008 · Cited by 21 · cited 1×
“[9–12] A fifth colposcopy study reported more complaints of discomfort in the C31G users, but similar colposcopic findings of epithelial disruption among users of 1.”
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502
McCormack, S., Ramjee, G., Kamali, A., Rees, H., Crook, A. M., Gafos, M., Jentsch, U., Pool, R., Chisembele, M., Kapiga, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61086-0 · Cited by 335
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic
Cohen, M. S., Hellmann, N., Levy, J. A., DeCock, K., & Lange, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34706 · Cited by 304
“However, multiple first-generation microbicides (nonoxynol-9, cellulose sulphate, and C31G [SAVVY]) have failed to protect in clinical trials (126–129).”
Metadata
- Authors
- Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W.
- Affiliations
- Family Health International 360 (US)
- Nigerian Institute of Medical Research (NG)
- University of Ibadan (NG)
- Corresponding author
- Feldblum, Paul J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-01-23
- Volume
- 3
- Issue
- 1
- Pages
- e1474
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2190795
- OpenAlex
- W2160780945
- Cited by
- 280
- References
- 28
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 2 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 2 · 2017: 5 · 2016: 6 · 2015: 14 · 2014: 22 · 2013: 27 · 2012: 42
- FWCI
- 27.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- United States Agency for International Development (GPO-A-00-05-00022-00)
- U.S. Food and Drug Administration
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- HIV prevention, vaginal microbicides, HIV seroconversion, HIV incidence, adverse events, chlamydia, vaginal infection
- MeSH terms
- Double-Blind Method, Female, Gels, Humans, Male, Nigeria, Patient Compliance, Placebos, Sexual Behavior, Vagina, HIV Infections, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
